{
  "figure_1": "Top: dual expression of TNF alpha (TNF‐α) and interleukin 2 (IL‐2) in CD4+ T cells in dasatinib treated patient. Left, pre‐vaccine; and right, post vaccine. Middle: dual expression of TNF‐α and interferon gamma (IFN‐γ) in CD4+ T cells in imatinib treated patient. Left, unstimulated cells; and right, cells exposed to S protein. Bottom: dual expression of IFN‐γ and IL‐2 in CD4+ T cells in nilotinib treated patient. Left, unstimulated cells; and right, cells exposed to S protein.",
  "figure_2": "(A) Mean increase in CD4+ T cell TNF alpha (TNF‐α) expression in nilotinib‐treated patients compared with other tyrosine kinase inhibitors (TKIs). (B) Mean increase in CD4+ T cell dual TNF‐α and interferon gamma (IFN‐γ) expression in nilotinib‐treated patients compared with other TKIs."
}